Just a week after WHO declared coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) a pandemic, on March 18, 2020, the agency launched a global clinical trial, named [SOLIDARITY](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments){#interrefs10}. Open to any country to participate, as of April 21, 2020, over 100 countries have signed up to take part in this single, large, randomised trial to find a treatment effective against COVD-19.

"As soon as COVID-19 broke out in China, we started looking into evidence in our research and development pipeline for repurposing any available drugs including those investigated in previous trials \[on SARS and MERS\]", said Soumya Swaminathan, Chief Scientist at WHO in Geneva. "From a long list of compounds that are postulated to potentially counter the \[SARS-CoV-2\] virus, we came up with a priority list of drugs that are known to be safe for human use", Swaminathan added.

The SOLIDARITY trial has four treatment groups: the Gilead antiviral remdesivir; the anti-HIV compounds lopinavir and ritonavir; a combination of lopinavir and ritonavir with the immune modulating interferon beta-1a, a multiple sclerosis drug; and finally, the antimalarials chloroquine and hydroxychloroquine, although their potential cardiotoxicity has caused much debate. The control group will be standard of care provided at hospitals as per the participating countries\' care guidelines.

"Right from the beginning, the idea was to set up a pragmatic trial---a trial that can happen in any hospital setting, even at the ones \[that\] do not have a research team", Swaminathan said. SOLIDARITY is an adaptive trial, allowing the addition of new arms as potential new treatments become available, or the dropping of arms for safety reasons. Patients will be randomly assigned using electronic health records by a centralised automated system at the WHO headquarters.

"I am very supportive of the trial because it is good to have an international effort in implementing a trial in many countries, which will be important to increase the sample size \[and\] is not restricted to high income countries only", said Julien Potet from the Médecins Sans Frontières Access Campaign. At the time of reporting, at least nine countries have started enrolling patients and over 35 African nations have shown interest for SOLIDARITY. WHO is guiding interested countries to set up the trial in their hospitals. "We are also making sure that trial participants can access the drugs", Swaminathan said.

India is one of the participating nations. Sheela Godbole from the National AIDS Research Institute, Pune, heads the team that will allocate both public and private hospitals that will do the trial, with the backing of the Indian Council of Medical Research. Participants will not have to pay for the SOLIDARITY trial drugs. "WHO will be gifting remdesivir and interferon beta-1a for the trial, but the other drugs are relatively inexpensive and we have secured enough supply", Godbole told *The Lancet Microbe*. "We will be either funding the \[participating\] hospitals to provide the drugs or we provide the drugs ourselves \[and\] we will have doctors available on call at the trial sites to solve problems in real time", Godbole said, declining, however, to comment on the control of care costs in private hospitals.

At the time of reporting, over 300 clinical trials have been launched pertaining to COVID-19, including the DisCoVeRy trial across several European locations, the UK-based RECOVERY trial, and the US UPMC-REMAP-COVID trial. However, despite the importance of finding potential therapies or vaccines, few trials include low-income and middle-income countries (LMICs), as does the SOLIDARITY trial. In response to this issue, on April 24, 2020, WHO launched the Global Collaboration to Accelerate the Development, Production, and Equitable Access to New COVID-19 diagnostics, therapeutics, and vaccines, known as the [ACT-Accelerator](https://www.who.int/news-room/detail/24-04-2020-commitment-and-call-to-action-global-collaboration-to-accelerate-new-covid-19-health-technologies){#interrefs20}. Similarly, to address issues such as constraints in standard of care in LMICs, a group of scientists, physicians, funders, and politicians from institutions across high-income countries and LMICs have launched a COVID-19 Clinical Research Coalition ([CCRC](https://covid19crc.org){#interrefs30}).

Working with other coalitions such as the COVID-19 Therapeutics Accelerator, the Coalition for Epidemic Preparedness Innovations, and the SARS-CoV-2 Diagnostic Pipeline, CCRC identifies roadblocks in countries that struggle to set up trial or care facilities and help them collaborate with institutions in their network, which could offer potential innovative solutions. "We try to collectively address barriers in conducting clinical research in such \[pandemic\] settings and make the solutions available to a greater number of researchers as opposed to just a few", said Philippe Guérin, Director of the Infectious Diseases Data Observatory at the University of Oxford (Oxford, UK) and member of CCRC.

The need for community trust and making drugs accessible after the trial, once their efficacy has been shown, are other notable concerns. "On one level there is an engagement between WHO and the governments \[in SOLIDARITY\]; but at the level of individual countries, it is crucial to ensure through community engagement that the participants are well aware of all the aspects of the trial," said Katharine Wright, bioethicist at the Nuffield Council of Bioethics (Nuffield, UK).
